Mode
Text Size
Log in / Sign up
Phase 2 Completed N=164 Treatment

Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)

Source: ClinicalTrials.gov NCT01275092 ↗
Enrolled (actual)
164
Serious AEs
17.1%
Results posted
Aug 2013
Primary outcomePrimary: Percentage of Participants With Clinical Procedural Success — 97.6 percentage of participants

Summary

The objective of this study is to evaluate the safety and effectiveness of the clinical and technical performance of the CorPath® 200 System in the delivery and manipulation of coronary guidewires and stent/balloon systems for use in percutaneous coronary interventions (PCI).

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Clinical Procedural Success
97.6 —
PRIMARY
Percentage of Patients With Device Technical Success
98.8 —
SECONDARY
The Ratio Between the Radiation Exposure of the Primary Operator and the Radiation Exposure at the Table
0.42 —

Eligibility Criteria

General Inclusion Criteria:

  • Subject is between 18 and 99 years of age.
  • Subject is an acceptable candidate for PCI.
  • Subject must have clinical evidence of ischemic heart disease or a positive functional study.
  • Female subjects must be of non-child bearing potential, or if able to bear children, have a negative pregnancy test within 7 days prior to the CorPath procedure.
  • The subject or the legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.

Angiographic Inclusion Criteria:

  • Study lesion is a single de novo native coronary artery lesion. This lesion may consist of multiple lesions (with 10mm or less between diseased segments) and must be completely covered by a single stent with at least 2.0mm of normal segments on proximal and distal edges of the lesion.
  • Study reference vessel diameter is between 2.5mm and 4.0mm by visual estimate.
  • Study lesion length is less than or equal to 24.0mm by visual estimate.
  • Study lesion diameter showing stenosis of at least 50% by visual estimate.

General Exclusion Criteria:

  • Subject requires planned PCI or CABG (Coronary Artery Bypass Graft) within 30 days following the CorPath procedure.
  • Evidence of an acute myocardial infarction within 72 hours prior to the intended CorPath procedure.
  • Subject has documented left ventricular ejection fraction 700,000 cells/mm3, or a WBC (white blood cell) count of 2.0 mg/dL or eGFR (estimated Glomerular Filtration Rate) 90°) proximal to the target lesion.
  • The study lesion has any of the following characteristics:
  • Total occlusion.
  • Ostial location.
  • Is within 2.0 mm of a side branch measuring >2.0 mm in diameter.
  • Located at < 45° bend in the vessel.
  • Moderately to severely calcified.
  • Moderate to severe calcification in the vessel proximal to the target lesion.
  • Located in a native vessel distal to an anastomosis, with a saphenous vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass, and is approached through the bypass graft.
  • Unprotected left main coronary artery disease defined as an obstruction greater than 50% diameter stenosis in the left main coronary artery.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01275092). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search